Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia

Exclusion Criteria

• •1. Treatment with cinacalcet hydrochloride within 2 weeks before screening
• •2. Change in dose or dosing regimen of an activated vitamin D drug or its derivative, phosphate binder, or Ca preparation within 2 weeks before screening; or start of treatment with such drugs within 2 weeks before screening
• •3. Change in prescribed conditions of dialysis (dialysate Ca concentration, prescribed dialysis time, and prescribed number of dialysis per week) within 2 weeks before screening
• •4. Treatment with bisphosphonates, denosumab or teriparatide within 24 weeks before screening
• •5. Parathyroidectomy and/or parathyroid intervention within 24 weeks before screening
• •6. Severe heart disease (e.g., ≧ Class Ⅲ per New York Heart Association classification)
• •7. Severe hepatic dysfunction (e.g., treatment with antiviral therapy)
• •8. Uncontrolled hypertension and/or diabetes